Abstract 1028: Evaluating amplitude modulated radiofrequency electromagnetic fields as a cancer screening modality

Abstract Background: Tumor-specific Amplitude Modulation Radiofrequency Electromagnetic Fields (AM RF EMF) have been identified in over 15 different tumor types. Tumor specific frequencies were identified by exposing patients with a known diagnosis of cancer to an AM RF EMF frequency sweep ranging from 0.1 Hz to 150 kHz. Frequencies that elicited an increase in pulse amplitude were registered as tumor-specific frequencies. We hypothesized that this mechanism could be used to screen for cancer, in which patients with an unknown diagnosis are exposed to previously identified tumor-specific frequencies and monitored for any change in hemodynamics. Methods: 17 patients with biopsy-proven hepatocellular carcinoma (HCC), 14 patients with biopsy-proven breast cancer (BC), and 31 healthy controls were recruited for the study and had their systolic blood pressure (sBP), diastolic blood pressure (dBP), pulse pressure (PP), cardiac output (CO), heart rate (HR) R-R interval (RRI), stroke volume (SV), and total peripheral resistance (TPR) measured while exposed to random (non-tumor-specific) AM RF EMF, HCC-specific AM RF EMF, and BC-specific AM RF EMF. Patient data was then used to train a one-dimensional convolutional neural network (1D CNN) to classify each dataset as control, HCC, or BC. Results: Overall accuracy for the model was 81.17%. AUC for the ROC curve for control, HCC, and BC was 0.91, 0.96, and 0.96 respectively. Conclusion: Our model demonstrates that AM RF EMF has the potential to be used as a cancer screening modality. Further studies will need to be performed with larger cohorts to validate the findings of this study and to improve the accuracy of the model. Additionally, future studies should investigate the potential for AM RF EMF-based screening for pancreatic cancer, as tumor-specific frequencies have previously been identified for the malady. Citation Format: Callum T. McGrath, Hugo Jimenez, Boris C. Pasche. Evaluating amplitude modulated radiofrequency electromagnetic fields as a cancer screening modality [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1028.